Provided by Tiger Trade Technology Pte. Ltd.

Oculis

28.48
+0.99003.60%
Post-market: 28.480.00000.00%16:58 EST
Volume:276.12K
Turnover:7.79M
Market Cap:1.63B
PE:-10.67
High:28.66
Open:27.61
Low:27.51
Close:27.49
52wk High:29.36
52wk Low:14.00
Shares:57.07M
Float Shares:46.06M
Volume Ratio:0.90
T/O Rate:0.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6693
EPS(LYR):-2.3426
ROE:-92.19%
ROA:-33.35%
PB:9.65
PE(LYR):-12.16

Loading ...

Coherent Dispels "Falling Behind" Concerns with Strong AI Client CPO Order and Robust Earnings

Deep News
·
Feb 05

Holding(s) in Company

GlobeNewswire
·
Feb 03

Holding(s) in Company

GlobeNewswire
·
Jan 31

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jan 22

AI Network Supercycle Extends to 2026, Top Winners Shift from "Easy Zhongtian" to "Zhongtian Taichang"?

Deep News
·
Jan 19

TransMedics Group: Buy Rating Reaffirmed on Durable Growth, OCS Platform Uptake, and Emerging Clinical and Geographic Catalysts

TIPRANKS
·
Jan 15

Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis

Simply Wall St.
·
Jan 11

Assessing Oculis Holding (OCS) Valuation After Privosegtor’s FDA Breakthrough Therapy Designation

Simply Wall St.
·
Jan 09

Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference

GlobeNewswire
·
Jan 08

Oculis Holding Up Over 11%, On Pace For Largest Percent Increase Since January 2025 -- Data Talk

Dow Jones
·
Jan 07

Oculis Shares Rise After Therapy Receives Breakthrough Designation from FDA

Dow Jones
·
Jan 06

Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis

GlobeNewswire
·
Jan 06

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Jan 06

Assessing Oculis Holding (NasdaqGM:OCS) Valuation After FDA Backing for OCS‑05 and PIONEER Program Progress

Simply Wall St.
·
Dec 23, 2025

Advancing Privosegtor Toward PIONEER Registrational Trials Could Be A Game Changer For Oculis (OCS)

Simply Wall St.
·
Dec 22, 2025

Oculis Holding Initiated at Overweight by JP Morgan

Dow Jones
·
Dec 19, 2025

JPMorgan Initiates Coverage on Oculis Holding AG With Overweight Rating, $38 Price Target

MT Newswires Live
·
Dec 19, 2025

Oculis Holding Ag : Stifel Raises Target Price to $40 From $35

THOMSON REUTERS
·
Dec 19, 2025

Noah Fund's Deng Xinyi: Profound Structural Evolution Underway Within AI Industry

Deep News
·
Dec 15, 2025

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Dec 10, 2025